Cancer drug delivery最新文献

筛选
英文 中文
Effect of vesicle size on the clearance, distribution, and tumor uptake of temperature-sensitive liposomes. 囊泡大小对温度敏感脂质体的清除、分布和肿瘤摄取的影响。
Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.223
R L Magin, J M Hunter, M R Niesman, G A Bark
{"title":"Effect of vesicle size on the clearance, distribution, and tumor uptake of temperature-sensitive liposomes.","authors":"R L Magin,&nbsp;J M Hunter,&nbsp;M R Niesman,&nbsp;G A Bark","doi":"10.1089/cdd.1986.3.223","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.223","url":null,"abstract":"<p><p>The blood clearance, tissue distribution, and tumor uptake of temperature-sensitive liposomes containing the anticancer drug cytosine [3H]-1-beta-D-arabino-furanoside (Ara-C) or [3H]-methotrexate (MTX) were measured. Large unilamellar liposomes composed of a mixture of dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol (4:1 by weight) were formed by reverse-phase evaporation and sequentially extruded through polycarbonate membranes with pore sizes of 0.4, 0.2, 0.1, 0.08, and 0.05 micron. The liposomes were injected intravenously via the tail vein into B6D2F1 mice containing solid tumors (M5076 ovarian carcinoma) implanted in both hind feet. Drug release, organ distribution, and tumor uptake were studied during and following local hyperthermia treatments (42 degrees C, 60 minutes). Local hyperthermia increased the relative amount of liposome encapsulated drug delivered to a heated solid tumor compared with the unheated control. The clearance studies showed that liposome blood clearance was inversely proportional to liposome size. However, tumor uptake was not significantly affected by reducing liposome size. In addition, for the range of liposome sizes studied, the majority of the liposome encapsulated drug was found in the liver, spleen, and kidney; not in the heated tumor.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 4","pages":"223-37"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14689714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay. 2-氯脱氧腺苷在人肿瘤集落形成试验中的细胞毒性。
Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.115
J J Hutton, D D Von Hoff
{"title":"Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.","authors":"J J Hutton,&nbsp;D D Von Hoff","doi":"10.1089/cdd.1986.3.115","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.115","url":null,"abstract":"<p><p>We have utilized a human tumor colony forming assay to test the antitumor activity of 2-chlorodeoxyadenosine and to compare its activity with that of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a related analog now in phase I/II clinical trials. The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for 2-chlorodeoxyadenosine was: 8% and 23% at 1.0 and 10.0 micrograms/ml as a 1 hour pulse exposure, respectively; 11% and 31% at 1.0 and 10.0 micrograms/ml, as a continuous exposure, respectively. 2-Chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine did not have identical spectra of antitumor activities in vitro, suggesting that both may be worthy of further clinical trial.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 2","pages":"115-22"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14009129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Phase II study of hepatic arterial degradable starch microspheres and mitomycin. 肝动脉可降解淀粉微球和丝裂霉素的二期研究。
Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.279
I S Wollner, S C Walker-Andrews, J E Smith, W D Ensminger
{"title":"Phase II study of hepatic arterial degradable starch microspheres and mitomycin.","authors":"I S Wollner,&nbsp;S C Walker-Andrews,&nbsp;J E Smith,&nbsp;W D Ensminger","doi":"10.1089/cdd.1986.3.279","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.279","url":null,"abstract":"<p><p>Twenty four patients with incurable primary or metastatic liver cancer were treated with hepatic arterial Mitomycin C admixed with degradable starch microspheres (DSM). Six objective responses (25% PR) were obtained in this heavily pretreated population with advanced disease. The median response duration was 3.5 months. Hematologic toxicity was minimal as would be expected from the reduced systemic exposure generated by the increased regional drug deposition. An apparent chemical hepatic arteritis developed in five patients after multiple courses, however, its relationship to prior hepatic arterial infusion therapies, Mitomycin, starch microspheres, and repeated dosing of the drug-microsphere mixture remains unclear. The responses seen in this study are encouraging given the heavily pretreated population in which they were obtained. Studies delineating the relative contribution of DSM to both the response and the toxicities of hepatic arterial Mitomycin and other appropriate antineoplastic agents in the treatment of single tumor types are needed.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 4","pages":"279-84"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.279","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14237944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
Drug sensitivity testing of carcinoma of the gallbladder and biliary tree in a human tumor cloning assay. 人肿瘤克隆试验中胆囊癌和胆道树的药物敏感性试验。
Cancer drug delivery Pub Date : 1986-01-01 DOI: 10.1089/cdd.1986.3.197
G J Harris, D D Von Hoff
{"title":"Drug sensitivity testing of carcinoma of the gallbladder and biliary tree in a human tumor cloning assay.","authors":"G J Harris,&nbsp;D D Von Hoff","doi":"10.1089/cdd.1986.3.197","DOIUrl":"https://doi.org/10.1089/cdd.1986.3.197","url":null,"abstract":"<p><p>We have received and attempted to culture 27 specimens from 26 patients with carcinoma of the gallbladder and biliary tree. Evaluable growth, defined as greater than or equal to 20 tumor colonies per control plate, was obtained in 8 (30%) of the specimens. Thirteen of the specimens (48%) did not grow and 6 (22%) were contaminated. The specimens with evaluable growth yielded 44 drug tests of which 12 (27%) resulted in less than or equal to 50% survival when compared to the untreated control plates. The standard chemotherapeutic agents carmusine (BCNU), cis-platinum, mitomycin-C, and vinblastine as well as the investigational agents mitoxantrone, acronycine, acivicin, and methylglyoxalbisguanylhydrazone (MGBG) demonstrated some in vitro activity and could be useful in carcinoma of the gallbladder and biliary tree. The human tumor cloning assay can be used to look for standard and investigational agents which should be tried against this relatively rare tumor.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"3 3","pages":"197-204"},"PeriodicalIF":0.0,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1986.3.197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14897918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo. 人肿瘤和白血病细胞体内缺乏二氢叶酸还原酶。
Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.133
B A Kamen, P A Nylen, V M Whitehead, H T Abelson, B J Dolnick, D W Peterson
{"title":"Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo.","authors":"B A Kamen,&nbsp;P A Nylen,&nbsp;V M Whitehead,&nbsp;H T Abelson,&nbsp;B J Dolnick,&nbsp;D W Peterson","doi":"10.1089/cdd.1985.2.133","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.133","url":null,"abstract":"<p><p>Dihydrofolate reductase (DHFR), the main target for methotrexate and other antifolate compounds was found to be present in 100-200 times higher concentration in human cell lines grown in vitro than in human tumors or cells obtained in situ. The DHFR content of human cell lines in vitro however were equivalent to rodent tumor lines also measured in vitro. The enzyme was quantitated by [3H]methotrexate binding, [3H]dihydrofolate reduction to [3H]tetrahydrofolate, and immunoprecipitation with a monospecific anti-serum to DHFR. Additional studies revealed only a liver sample to contain significant amounts of an inhibitor of DHFR activity. It is postulated either that low levels of DHFR in fresh human tissue reflect low cell turnover or conversely that high levels in vitro and in animal tissues reflect high levels of enzyme due to selection because of high levels of folic acid in culture medium and prepared feeds.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 2","pages":"133-8"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15164896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 36
Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma. 腹膜间皮瘤患者每日腹腔内给予阿糖胞苷。
Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.285
M Markman, S B Howell
{"title":"Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma.","authors":"M Markman,&nbsp;S B Howell","doi":"10.1089/cdd.1985.2.285","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.285","url":null,"abstract":"<p><p>A 58 year old male with advanced peritoneal malignant mesothelioma was treated with the daily (5 days/week) intraperitoneal administration of cytarabine in a large treatment volume (1-2 liters) for 7 weeks. While a clinical benefit was not observed, there was no systemic toxicity (except for mild emesis) during or following the intraperitoneal treatment program. Long-term exposure of slow growing solid tumors in the peritoneal cavity to a cell-cycle phase-specific agent with limited systemic exposure and toxicity is an innovative and potentially important means of rationally utilizing this class of anti-neoplastic drugs.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 4","pages":"285-9"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15175450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The effect of iron dextran on ferritin content and 131I-antiferritin localization in experimental hepatomas. 右旋糖酐铁对实验性肝癌中铁蛋白含量及131i -抗铁蛋白定位的影响。
Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.3
R A Rostock, K A Kopher, T W Bauer, J L Klein
{"title":"The effect of iron dextran on ferritin content and 131I-antiferritin localization in experimental hepatomas.","authors":"R A Rostock,&nbsp;K A Kopher,&nbsp;T W Bauer,&nbsp;J L Klein","doi":"10.1089/cdd.1985.2.3","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.3","url":null,"abstract":"<p><p>Polyclonal 131I rabbit antirat ferritin localizes in certain hepatoma models. The effect of intraperitoneal iron dextran on tumor and sera ferritin content and tumor and normal tissue localization with 131I antiferritin was studied. Separate groups of 10-12 animals were injected with escalating doses of 131I-antiferritin IgG, or nonspecific IgG, one week after injection with iron dextran or normal saline. The results demonstrate that tumor, serum, and normal tissue ferritin content was increased after iron dextran administration but tumor localization increased after administration of 131I-antiferritin in the H4II-E and 7800 models. The 3924A and 7777 models showed no tumor localization with or without iron dextran but did show an increase in normal tissue localization after iron dextran. Immunoperoxidase staining of tissues with antiferritin revealed increased staining in the liver and spleen and only a slight increase in the tumors after iron dextran was administered. The results demonstrate that tumor localization is a complex phenomenon that depends on normal tissue, sera, and tumor-antigen distribution.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 1","pages":"3-9"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15016839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The intraoperative intraperitoneal administration of cisplatin: a case report. 术中腹腔给药顺铂1例。
Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.87
M Markman, R Weiss, S B Howell, W E Lucas
{"title":"The intraoperative intraperitoneal administration of cisplatin: a case report.","authors":"M Markman,&nbsp;R Weiss,&nbsp;S B Howell,&nbsp;W E Lucas","doi":"10.1089/cdd.1985.2.87","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.87","url":null,"abstract":"<p><p>A 63-year-old female with endometrial carcinoma who had received prior extensive systemic chemotherapy and pelvic radiotherapy was administered intraoperative cisplatin (100 mg/m2) by the i.p. route. The method and timing of chemotherapy administration were chosen to optimize delivery of the antineoplastic agent to tumor remaining following debulking surgery. There was no evidence of excessive or unexpected local or systemic toxicity. The intraoperative i.p. instillation of chemotherapeutic agents has the theoretical potential of improving to a limited degree the problem of insuring adequate drug distribution over i.p. chemotherapy.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 2","pages":"87-90"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.87","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15164897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance. 大剂量甲氨蝶呤输注的剂量预测。第2部分:甲氨蝶呤清除率的贝叶斯估计。
Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.277
R Bruno, A Iliadis, R Favre, N Lena, A M Imbert, J P Cano
{"title":"Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance.","authors":"R Bruno,&nbsp;A Iliadis,&nbsp;R Favre,&nbsp;N Lena,&nbsp;A M Imbert,&nbsp;J P Cano","doi":"10.1089/cdd.1985.2.277","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.277","url":null,"abstract":"<p><p>Population pharmacokinetics of methotrexate (MTX) was evaluated from intravenous test-dose (TD) data (n = 20 corresponding to 174 measured samples). Bayesian prediction of MTX clearance from TD experiments combining population data with measured levels (at times 0.5 and 6 h) was found to be feasible in routine situations with good performance (root mean squared error : rmse (precision) = 1.14 1.h-1 (11.2%) and mean error : me (bias) = 0.06 1.h-1 (NS) relatively to weighted least-square estimates, n = 50). The precision of Bayesian prediction was comparable to that of the model independent which is used in routine practice and involves 9 measured levels over 30 h, (rmse = 1.35 1.h-1 (10.9%), n = 50). However, the routine method presented a significative bias (me = -0.81 1.h-1, n = 50).</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 4","pages":"277-83"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.277","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"15175449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro. 含有蓖麻毒素A链或B链的免疫毒素与修饰的碳水化合物残基在体外协同杀死肿瘤B细胞。
Cancer drug delivery Pub Date : 1985-01-01 DOI: 10.1089/cdd.1985.2.191
E S Vitetta, P E Thorpe
{"title":"Immunotoxins containing ricin A or B chains with modified carbohydrate residues act synergistically in killing neoplastic B cells in vitro.","authors":"E S Vitetta,&nbsp;P E Thorpe","doi":"10.1089/cdd.1985.2.191","DOIUrl":"https://doi.org/10.1089/cdd.1985.2.191","url":null,"abstract":"<p><p>Partially deglycosylated (dg) ricin A and B chains were coupled to rabbit anti-human Ig (IT-dg-A) and goat anti-rabbit Ig (IT-dg-B), respectively. The deglycosylation was accomplished by treating intact ricin (before separation into its constituent chains) with a mixture of sodium metaperiodate and sodium cyanoborohydride. The two immunotoxins (ITs) acted synergistically in vitro to kill Daudi cells, albeit to a four-to-eight-fold lesser degree than ITs prepared with native A and B chains.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"2 3","pages":"191-8"},"PeriodicalIF":0.0,"publicationDate":"1985-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1985.2.191","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14993855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信